These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19601813)

  • 41. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
    Sun J; Liu L; Jiang X; Chen D; Huang Y
    Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
    Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T
    Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
    Schaefer S; Svenstrup TH; Guerra B
    PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Organelle-specific Hsp90 inhibitors.
    Seo YH
    Arch Pharm Res; 2015 Sep; 38(9):1582-90. PubMed ID: 26195286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
    J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
    Bansal H; Bansal S; Rao M; Foley KP; Sang J; Proia DA; Blackman RK; Ying W; Barsoum J; Baer MR; Kelly K; Swords R; Tomlinson GE; Battiwalla M; Giles FJ; Lee KP; Padmanabhan S
    Blood; 2010 Nov; 116(22):4591-9. PubMed ID: 20651072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].
    Chen KK; He ZM; Ding BH; Chen Y; Zhang LJ; Yu L; Gao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):117-21. PubMed ID: 26913406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
    Bareng J; Jilani I; Gorre M; Kantarjian H; Giles F; Hannah A; Albitar M
    Leuk Lymphoma; 2007 Nov; 48(11):2189-95. PubMed ID: 17926180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein chaperones as anticancer therapy targets.
    Sausville E
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
    [No Abstract]   [Full Text] [Related]  

  • 55. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel class of small molecule inhibitors of Hsp90.
    Yi F; Regan L
    ACS Chem Biol; 2008 Oct; 3(10):645-54. PubMed ID: 18785742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
    Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
    Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.